Ann Hematol: 免疫性血小板减少症发展为系统性红斑狼疮的潜在危险因素:中国儿童病例对照研究

2022-05-19 网络 网络

建议对儿科 ITP 患者进行至少 3 年的密切随访,以监测发生 SLE 的风险。高龄和低补体血症是从 ITP 发展为 SLE 的潜在危险因素。

免疫性血小板减少症 (ITP) 患者未来有发展为系统性红斑狼疮 (SLE) 的风险。一研究团队试图通过统计分析探讨中国儿童从 ITP 发展为 SLE 的潜在危险因素。

研究为回顾性病例对照研究。将诊断为 ITP 并在 ITP 诊断后发展为 SLE 的患者定义为病例组。对照组由患有 ITP 但未发展为 SLE 的儿童组成,比例为 1:2。除了单变量分析外,还建立了多变量逻辑回归来评估潜在的危险因素。共纳入150名儿童,其中病例组50名,对照组100名。

表1:ITP发生SLE组与原发性ITP组的临床表现。缩写:ITP,免疫性血小板减少症;SLE,系统性红斑狼疮;OR,优势比;CI,置信区间;CTD, 结缔组织病

表2:ITP发生SLE组与原发性ITP组之间的血小板和巨核细胞计数

表3:从ITP~SLE等潜在危险因素的多变量分析。缩写:ANA,抗核抗体;C3,补体3;C4,补体4。

 

从 ITP 到 SLE 的中位发展时间为 34.5 [IQR 12.5, 58.75] 个月。在该研究中,ANA 在单变量分析中发现两组之间存在显著差异,但在多变量分析中没有发现(OR = 4.50,95% CI 0.97 - 21.01)。诊断出的 ITP 与 SLE 呈正相关(OR = 1.07 每 5 年,95% CI 1.01 - 1.15),8 岁时有警报点(敏感性 0.82,特异性 0.60)。较低水平的补体也与 SLE 呈正相关(OR = 8.33,95% CI 1.62 - 42.91)。

综上所述,研究人员首次对50例发展为SLE的ITP患儿和100例未发展为SLE的原发性ITP患儿进行回顾性病例对照研究,探讨发展为SLE的潜在危险因素。从ITP到SLE的中位发展时间为2.9年。

因此,研究建议对儿科 ITP 患者进行至少 3 年的密切随访,对有多种危险因素的患儿进行长达10年的随访,以监测发生 SLE 的风险。随访期间伴有低补体血症的儿童ITP患者未来发生SLE的风险更高。同时,年龄较大的ITP患儿,尤其是8岁以上的患儿,发生SLE的风险明显增加,需要密切随访。ANA阳性可能在一定程度上影响ITP患儿SLE的发展

 

原始出处:

Song, Y., Zhang, Y., Li, Z. et al. Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese children. Ann Hematol (2022). https://doi.org/10.1007/s00277-022-04836-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2023-01-19 amyloid
  3. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2023-05-03 xugc
  4. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 fengyi812
  8. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2017367, encodeId=666d201e367d4, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Apr 04 02:30:07 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775642, encodeId=7bf11e75642df, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Thu Jan 19 15:30:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756184, encodeId=55b61e56184d8, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed May 03 07:30:07 CST 2023, time=2023-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984152, encodeId=9d57198415241, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Jan 12 04:30:07 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754095, encodeId=8b9f1e54095c4, content=<a href='/topic/show?id=5db12902447' target=_blank style='color:#2F92EE;'>#免疫性血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29024, encryptionId=5db12902447, topicName=免疫性血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed4d36658977, createdName=lily1628, createdTime=Thu Aug 18 06:30:07 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302887, encodeId=34b7130288ea3, content=<a href='/topic/show?id=9c72890153c' target=_blank style='color:#2F92EE;'>#血小板减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89015, encryptionId=9c72890153c, topicName=血小板减少)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317715, encodeId=383e131e715d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387534, encodeId=969b138e5346f, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436342, encodeId=c8ac14363428d, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 20 10:30:07 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 zhouqu_8

相关资讯

NEJM:吗替麦考酚酯可作为免疫性血小板减少症患者的一线治疗

将吗替麦考酚酯添加到糖皮质激素中用于免疫性血小板减少症的一线治疗可获得更大的治疗反应,并降低难治性或复发性免疫性血小板减少症的风险,但生活质量有所下降。

NEJM:口服利扎鲁替尼治疗免疫性血小板减少症的疗效

在所有剂量水平下,利扎鲁替尼都是有效的,且仅与低水平的毒性作用相关。总的来说,利扎鲁替尼具有快速和持久的临床活性,并随着治疗时间的延长而有所改善。

Clin Exp Med:免疫性血小板减少症治疗反应期间血小板活性和周转指数的变化

血小板活性标志物(sP-选择素和 sCD40L)和 GC 指数与治疗反应平行变化。GC 和 sCD40L 的血浆水平可能是治疗反应的预测因子

BJH:免疫性血小板减少症成人在接受艾曲波帕或罗米司亭治疗后改用阿凡波帕:一项多中心美国研究

阿凡波帕在使用罗米司亭或艾曲波帕治疗后有效,即使在对先前 TPO-RA 反应不足的患者中也具有高反应率。

NEJM:疫苗诱导免疫性血小板减少症和血栓形成的临床特征

在血小板计数降低和颅内出血的患者中,与VITT相关的死亡率最高。治疗仍然不确定,但识别预后标志物可能有助于指导有效治疗。

Lancet Haematol:全反式视黄酸加大剂量地塞米松可作为新诊断免疫性血小板减少症患者的一线治疗

全反式维甲酸和大剂量地塞米松的组合在新诊断的原发性免疫性血小板减少症患者中是安全且有效的,提供了持续的反应。该方案代表了这种情况下潜在的一线治疗,但需要进一步研究以验证其有效性和安全性。

拓展阅读

Blood:HLA表位抗原错配对输血小板的效果的影响

血小板输注无效会导致不良预后和增加医疗费用。处理由于HLA同种异体免疫引起的难治性,需要使用HLA抗原匹配的血小板,但需要大量的血小板捐献者,并且不能保证完全匹配。

Blood:免疫性血小板减少研究新进展

近日,北京大学人民医院血液病研究所、北大-清华生命科学联合中心研究员黄晓军教授课题组的研究成果“Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients”,作为封面文章发表在最新一期血液学顶级权威期刊Blood上。北

免疫性血小板减少病人的romiplostim或标准治疗

  背景 Romiplostim,一种血小板生成素模拟物,增加免疫性血小板减少病人的血小板计数,而且几乎没有不良反应。   方法 在这项开放标签、为期52周的研究中,我们将234例患有免疫性血小板减少但没有接受脾切除术的成年病人,随机分配接受标准治疗(77例病人)或每周1次皮下注射romiplostim(157例病人)治疗。主要终点是治疗失败和脾切除术的发生率。次要终点包括血小板反应率(在任何

2021 THANZ共识指南:成人免疫性血小板减少症的管理

澳大利亚和新西兰血栓与止血学会(THANZ,Thrombosis and Haemostasis society of Australia and New Zealand) · 2021-10-10